Variation in Inhaled Medication Use for Infants With Congenital Heart Disease and Bronchiolitis

Abstract

BACKGROUND AND OBJECTIVES Current viral bronchiolitis guidelines exclude infants with congenital heart disease (CHD). Variations in the use of common therapeutics in this population and their associations with clinical outcomes are unknown. Our objective was to evaluate variations in (1) the use of β-2-agonists and hypertonic saline across hospitals among infants with CHD hospitalized with bronchiolitis, and (2) hospital-level associations between medication use and outcomes. METHODS We performed a multicenter retrospective cohort study using administrative data from 52 hospitals in the Pediatric Health Information System. We included infants ≤12 months old hospitalized from January 1, 2015 to June 30, 2019 for bronchiolitis with a secondary diagnosis of CHD. Primary exposures were the hospital-level proportion of days that patients received β-2-agonists or hypertonic saline. Linear regression models assessed the association between the primary exposure and length of stay, 7-day readmission, mechanical ventilation use, and ICU utilization, adjusting for patient covariates and accounting for clustering by center. RESULTS We identified 6846 index hospitalizations for bronchiolitis in infants with CHD. Overall, 43% received a β-2-agonist, and 23% received hypertonic saline. The proportion of days with the use of β-2-agonists (3.6% to 57.4%) and hypertonic saline (0.0% to 65.8%) varied widely across hospitals in our adjusted model. For both exposures, adjusted models revealed no association between days of use and patient outcomes. CONCLUSIONS For children with CHD hospitalized with bronchiolitis, hospital-level use of β-2-agonists and hypertonic saline varied widely, and their use was not associated with clinical outcomes.